Scribe Therapeutics Inc. (NasdaqGM: SCTX)
Health Care · Biotechnology · US
$20.73
-20.27% today · -4.2% 1Y
Scribe Therapeutics Inc. (NasdaqGM: SCTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $391.06M and employs 89 people.
Over the last twelve months the share price has lost 4.2%, trading between 17.31 and 26.50.
SCTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $391.06M
- Revenue (TTM)
- $36.28M
- P/E
- —
- EPS
- -14.64
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $26.50
- 52-week low
- $17.31
- Avg volume (3M)
- —
- Shares outstanding
- 18.86M
- Employees
- 89
- Next earnings
- —
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
- ISIN
- US8110331092
- Founded
- 2017
- Listed since
- Jul 24, 2026
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.